Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC

NCT02659514 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT02659514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02659514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Completed
Start date
February 22, 2016
Completion date
March 11, 2020
Enrollment
67 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer